Different signaling responses to anti-proliferative agents in human aortic and venous smooth muscle cells

Journal of Cellular Biochemistry

Volumn 99, Issue 3, 2006, Pages 835-844

  Lee, Ray M ^a,b,e   Masaki, Takahisa ^a   Yang, Hung Sheng ^b   Liu, Jihua ^b   Chen, Jun ^b   Li, Li ^a   Blumenthal, Donald K ^c   Cheung, Alfred K ^a,d  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Akt; MAPK; Signal transduction; Smooth muscle cells; Vascular access stenosis

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 4 (4 FLUOROPHENYL) 2 (4 NITROPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; BROXURIDINE; ETOPOSIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PACLITAXEL; PROTEIN KINASE B;

APOPTOSIS; ARTICLE; BLOOD VESSEL GRAFT; CELL PROLIFERATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MITOCHONDRION; PRIORITY JOURNAL; SAPHENOUS VEIN; SIGNAL TRANSDUCTION; SKIN FIBROBLAST; SMOOTH MUSCLE FIBER;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AORTA; CELL PROLIFERATION; CELLS, CULTURED; ETOPOSIDE; FIBROBLASTS; HUMANS; MAP KINASE SIGNALING SYSTEM; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-AKT; SAPHENOUS VEIN; TUBULIN MODULATORS;

EID: 33749484996     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.20903     Document Type: Article

References (38)

1. Ajani AE, Waksman R. 2004. Paclitaxel-eluting coronary stents. N Engl J Med 350:2099-2100.
2. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR. 1995. PD 098059 is a specific inhibitor of the activation of mitogen- activated protein kinase kinase in vitro and in vivo. J Biol Chem 270:27489-27494.
3. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, Hemmings BA. 1996. Mechanism of activation of protein kinase B by insulin and IGF-1. Embo J 15:6541-6551.
4. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, Cohen P. 1997. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 7:261-269.
5. Allan LA, Morrice N, Brady S, Magee G, Pathak S, Clarke PR. 2003. Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK. Nat Cell Biol 5:647-654.
6. Axel DI, Kunert W, Goggelmann C, Oberhoff M, Herdeg C, Kuttner A, Wild DH, Brehm BR, Riessen R, Koveker G, Karsch KR. 1997. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 96:636-645.
7. Brunet A, Park J, Tran H, Hu LS, Hemmings BA, Greenberg ME. 2001. Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a). Mol Cell Biol 21:952-965.
8. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S, Reed JC. 1998. Regulation of cell death protease caspase-9 by phosphorylation. Science 282:1318-1321.
9. Chan TO, Tsichlis PN. 2001. PDK2: A complex tail in one Akt. Sci STKE 2001:E1.
10. Chang CJ, Ko PJ, Hsu LA, Ko YS, Ko YL, Chen CF, Huang CC, Hsu TS, Lee YS, Pang JH. 2004. Highly increased cell proliferation activity in the restenotic hemodialysis vascular access after percutaneous transluminal angioplasty: Implication in prevention of restenosis. Am J Kidney Dis 43:74-84.
11. Chen Z, Gibson TB, Robinson F, Silvestro L, Pearson G, Xu B, Wright A, Vanderbilt C, Cobb MH. 2001. MAP kinases. Chem Rev 101:2449-2476.
12. Cho H, Mu J, Kim JK, Thorvaldsen JL, Chu Q, Crenshaw EB III, Kaestner KH, Bartolomei MS, Shulman GI, Birnbaum MJ. 2001. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 292:1728-1731.
13. Clark AS, West K, Streicher S, Dennis PA. 2002. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 1:707-717.
14. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME. 1997. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91:231-241.
15. Datta SR, Brunet A, Greenberg ME. 1999. Cellular survival: A play in three Akts. Genes Dev 13:2905-2927.
16. de la Llera-Moya M, Rothblat GH, Glick JM, England JM. 1992. Etoposide treatment suppresses atherosclerotic plaque development in cholesterol-fed rabbits. Arterioscler Thromb 12:1363-1370.
17. Deng X, Ruvolo P, Carr B, May WS, Jr. 2000. Survival function of ERK1/2 as IL-3-activated, staurosporine-resistant Bcl2 kinases. Proc Natl Acad Sci USA 97:1578-1583.
18. English JM, Cobb MH. 2002. Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci 23:40-45.
19. Kanterman RY, Vesely TM, Pilgram TK, Guy BW, Windus DW, Picus D. 1995. Dialysis access grafts: Anatomic location of venous stenosis and results of angioplasty. Radiology 195:135-139.
20. Kim SJ, Masaki T, Leypoldt JK, Kamerath CD, Mohammad SF, Cheung AK. 2004. Arterial and venous smooth-muscle cells differ in their responses to antiproliferative drugs. J Lab Clin Med 144:156-162.
21. Kim D, Dan HC, Park S, Yang L, Liu Q, Kaneko S, Ning J, He L, Yang H, Sun M, Nicosia SV, Cheng JQ. 2005. AKT/PKB signaling mechanisms in cancer and chemoresistance. Front Biosci 10:975-984.
22. Kumar P, Miller AI, Polverini PJ. 2004. p38 MAPK mediates gamma-irradiation-induced endothelial cell apoptosis, and vascular endothelial growth factor protects endothelial cells through the phosphoinositide 3-kinase-Akt-Bcl-2 pathway. J Biol Chem 279:43352-43360.
23. Kummer JL, Rao PK, Heidenreich KA. 1997. Apoptosis induced by withdrawal of trophic factors is mediated by p38 mitogen-activated protein kinase. J Biol Chem 272:20490-20494.
24. Le Gall M, Chambard JC, Breittmayer JP, Grail D, Pouyssegur J, Van Obberghen-Schilling E. 2000. The p42/p44 MAP kinase pathway prevents apoptosis induced by anchorage and serum removal. Mol Biol Cell 11:1103-1112.
25. Linde J, Strauss BH. 2001. Pharmacological treatment for prevention of restenosis. Expert Opin Emerg Drugs 6:281-302.
26. Masaki T, Rathi R, Zentner G, Leypoldt JK, Mohammad SF, Burns GL, Li L, Zhuplatov S, Chirananthavat T, Kim SJ, Kern S, Holman J, Kim SW, Cheung AK. 2004. Inhibition of neointimal hyperplasia in vascular grafts by sustained perivascular delivery of paclitaxel. Kidney Int 66:2061-2069.
27. Park SJ, Shim WH, Ho DS, Raizner AE, Park SW, Hong MK, Lee CW, Choi D, Jang Y, Lam R, Weissman NJ, Mintz GS. 2003. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med 348:1537-1545.
28. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH. 2001. Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions. Endocr Rev 22:153-183.
29. Roy-Chaudhury P, Kelly BS, Miller MA, Reaves A, Armstrong J, Nanayakkara N, Heffelfinger SC. 2001. Venous neointimal hyperplasia in polytetrafluoroethylene dialysis grafts. Kidney Int 59:2325-2334.
30. Scott S, O'Sullivan M, Hafizi S, Shapiro LM, Bennett MR. 2002. Human vascular smooth muscle cells from restenosis or in-stent stenosis sites demonstrate enhanced responses to p53: Implications for brachytherapy and drug treatment for restenosis. Circ Res 90:398-404.
31. Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J, Arteaga CL. 2002. PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat Med 8:1145-1152.
32. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME. 2004. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350:221-231.
33. Swedberg SH, Brown BG, Sigley R, Wight TN, Gordon D, Nicholls SC. 1989. Intimal fibromuscular hyperplasia at the venous anastomosis of PTFE grafts in hemodialysis patients. Clinical, immunocytochemical, light and electron microscopic assessment. Circulation 80:1726-1736.
34. Thompson JE, Thompson CB. 2004. Putting the rap on Akt. J Clin Oncol 22:4217-4226.
35. von Gise A, Lorenz P, Wellbrock C, Hammings B, Berberich-Siebelt F, Rapp UR, Troppmair J. 2001. Apoptosis suppression by Raf-1 and MEK1 requires MEK- and phosphatidylinositol 3-kinase-dependent signals. Mol Cell Biol 21:2324-2336.
36. Waugh J, Wagstaff AJ. 2004. The paclitaxel (TAXUS)-eluting stent: A review of its use in the management of de novo coronary artery lesions. Am J Cardiovasc Drugs 4:257-268.
37. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. 1995. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270:1326-1331.
38. Zdychova J, Komers R. 2005. Emerging role of Akt kinase/protein kinase B signaling in pathophysiology of diabetes and its complications. Physiol Res 54:1-16.